title: Delays to reperfusion therapy in acute ST-segment elevation myocardial infarction: results from the AMI-QUEBEC Study.
abstract: BACKGROUND
  Through the AMI-QUEBEC Study we sought to describe delays to reperfusion therapy for ST-segment elevation myocardial infarction (STEMI) and to identify factors associated with prolonged delays.
  
  
  METHODS
  We reviewed the charts of all consecutive patients with STEMI admitted to 17 hospitals in the province of Quebec in 2003 to obtain data on the time from presentation to reperfusion therapy. Data were available for 1189 (83.0%) of 1432 patients.
  
  
  RESULTS
  The median delay to reperfusion therapy was 32 minutes (first and third quartile [Q1, Q3] 20, 49) for 535 patients who received fibrinolytic therapy, 109 minutes (Q1, Q3 79, 150) for 455 patients who underwent primary percutaneous coronary intervention (PCI) at the initial hospital of presentation and 142 minutes (Q1, Q3 115, 194) for 199 patients who underwent primary PCI after an interhospital transfer. Patients who presented outside daytime working hours, those who received primary PCI and those who required interhospital transfer for primary PCI were less likely to receive reperfusion therapy within current recommended times (odds ratios [ORs] 0.49, 0.56 and 0.15, respectively). Increased age was associated with prolonged delays only among patients who received fibrinolytic therapy (OR for each 10-year increase in age 0.95, 95% credible interval [CrI] 0.93-0.99 for fibrinolytic therapy and 0.99, 95% CrI 0.95-1.05, for primary PCI).
  
  
  CONCLUSIONS
  In 2003, many patients with STEMI in Quebec were not treated within the recommended times. Delays may be reduced by reorganizing pre-and in-hospital care for patients with STEMI to expedite delivery of reperfusion therapy.
authors.affiliation: Division of Cardiology, Department of Cardiology, Montreal General Hospital, Montréal, Quebec, Canada. thao.huynhthanh@mail.mcgill.ca
authors.forename: Thao
authors.initials: T
authors.lastname: Huynh
authors.forename: Jennifer
authors.initials: J
authors.lastname: O'Loughlin
authors.forename: Lawrence
authors.initials: L
authors.lastname: Joseph
authors.forename: Erick
authors.initials: E
authors.lastname: Schampaert
authors.forename: Stéphane
authors.initials: S
authors.lastname: Rinfret
authors.forename: Marc
authors.initials: M
authors.lastname: Afilalo
authors.forename: Simon
authors.initials: S
authors.lastname: Kouz
authors.forename: Bernard
authors.initials: B
authors.lastname: Cantin
authors.forename: Michel
authors.initials: M
authors.lastname: Nguyen
authors.forename: Mark J
authors.initials: MJ
authors.lastname: Eisenberg
mesh_terms: D000367:Age Factors; D000368:Aged; D017130:Angioplasty / Q000706:statistics & numerical data; D004562:Electrocardiography; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D019983:Guideline Adherence; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000628:therapy*; D015425:Myocardial Reperfusion; D011379:Prognosis; D012189:Retrospective Studies; D013997:Time Factors
chemical_list: D005343:Fibrinolytic Agents